{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:22:04Z","timestamp":1778858524319,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NHRMC","award":["APP1022451"],"award-info":[{"award-number":["APP1022451"]}]},{"name":"NHRMC","award":["APP1077703"],"award-info":[{"award-number":["APP1077703"]}]},{"name":"NHRMC","award":["APP1079422"],"award-info":[{"award-number":["APP1079422"]}]},{"name":"Monash Fellowship"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuropharm.2017.04.010","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T04:33:00Z","timestamp":1491625980000},"page":"55-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide"],"prefix":"10.1016","volume":"123","author":[{"given":"Aneta","family":"Stefanidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Oldfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.04.010_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/mp.2010.33","article-title":"Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis","volume":"16","author":"Albaugh","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib2","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A\u00a0double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/schbul\/sbq053","article-title":"Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents","volume":"38","author":"Albaugh","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4088\/JCP.v65n0417","article-title":"Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics","volume":"65","author":"Almeras","year":"2004","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib5","series-title":"Appetite Control","first-page":"433","article-title":"Weight-reducing side effects of the Antiepileptic agents topiramate and zonisamide","author":"Antel","year":"2012"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v65n1007","article-title":"Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients","volume":"65","author":"Arranz","year":"2004","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2008.06.105","article-title":"The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063","volume":"592","author":"Assie","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","article-title":"Clinical pharmacology and mechanism of action of zonisamide","volume":"30","author":"Biton","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1345\/aph.1G564","article-title":"Naturalistic impact of second-generation antipsychotics on weight gain","volume":"40","author":"Brixner","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in\u00a0vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/diabetes.51.4.1005","article-title":"The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments","volume":"51","author":"Cnop","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/rp.56.1.309","article-title":"The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis","volume":"56","author":"Collins","year":"2001","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib15","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without Concomitant AMPK phosphorylation","volume":"6","author":"Fern\u00f8","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/14656560902824152","article-title":"Combination pharmaceutical therapies for obesity","volume":"10","author":"Gadde","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib17","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","article-title":"Zonisamide for weight loss in obese adults: a randomized controlled trial","volume":"289","author":"Gadde","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib18","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1038\/ijo.2008.246","article-title":"2008. Energy metabolism, fuel selection and body weight regulation","volume":"32","author":"Galgani","year":"2005","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00210-013-0933-5","article-title":"Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects","volume":"387","author":"Girault","year":"2014","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2017.04.010_bib20","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","volume":"35","author":"Gobira","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","article-title":"Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine","volume":"159","author":"Gothelf","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1463-1326.2004.00413.x","article-title":"Antipsychotic-induced weight gain","volume":"7","author":"Goudie","year":"2005","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","article-title":"The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain","volume":"27","author":"He","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psyneuen.2014.01.018","article-title":"Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats","volume":"42","author":"He","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psyneuen.2016.07.218","article-title":"Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats","volume":"73","author":"Horska","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1172\/JCI10842","article-title":"Obesity and insulin resistance","volume":"106","author":"Kahn","year":"2000","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in\u00a0vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF02256023","article-title":"Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats","volume":"9","author":"Kuo","year":"2002","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cmet.2006.03.005","article-title":"Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome","volume":"3","author":"Lass","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-8993(98)00186-3","article-title":"Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats","volume":"793","author":"Lecklin","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The schizophrenia patient outcomes research Team (PORT): updated treatment recommendations 2003","volume":"30","author":"Lehman","year":"2004","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib37","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lfs.2015.01.033","article-title":"Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats","volume":"128","author":"Liu","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib40","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/npp.2010.21","article-title":"Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis","volume":"35","author":"Maayan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2015.11.011","article-title":"A\u00a0systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia","volume":"170","author":"Malan-M\u00fcller","year":"2016","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib42","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"Martins","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e3182488758","article-title":"A\u00a0randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain","volume":"32","author":"McElroy","year":"2012","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.mp.4001948","article-title":"Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment","volume":"12","author":"Minet-Ringuet","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis","volume":"40","author":"Mizuno","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0166-4328(01)00225-X","article-title":"Brain histamine and feeding behavior","volume":"124","author":"Morimoto","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0920-1211(98)00109-0","article-title":"Biphasic effects of zonisamide on serotonergic system in rat hippocampus","volume":"34","author":"Okada","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125312464385","article-title":"The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review","volume":"3","author":"Papanastasiou","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11010-006-9160-4","article-title":"SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?","volume":"289","author":"Raeder","year":"2006","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib52","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/schbul\/sbn104","article-title":"Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation","volume":"36","author":"Savoy","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib53","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/j.1440-1614.2006.01888.x","article-title":"Energy expenditure and physical activity in clozapine use: implications for weight management","volume":"40","author":"Sharpe","year":"2006","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"Skrede","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug-induced weight gain","volume":"17","author":"Stefanidis","year":"2009","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.beem.2014.08.001","article-title":"Hypothalamic control of adipose tissue","volume":"28","author":"Stefanidis","year":"2014","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eplepsyres.2008.07.008","article-title":"Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition","volume":"82","author":"Supuran","year":"2008","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib58","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib59","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/153537020222700309","article-title":"Hypothalamic histamine neurons activate lipolysis in rat adipose tissue","volume":"227","author":"Tsuda","year":"2002","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S146114571300093X","article-title":"Modelling olanzapine-induced weight gain in rats","volume":"17","author":"van der Zwaal","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2007.11.078","article-title":"Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution","volume":"585","author":"van der Zwaal","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2010.05.009","article-title":"Olanzapine affects locomotor activity and meal size in male rats","volume":"97","author":"van der Zwaal","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib63","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":"Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis","volume":"32","author":"Vestri","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib64","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1038\/npp.2008.9","article-title":"Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats","volume":"33","author":"Wallingford","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2007.05.007","article-title":"Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells","volume":"56","author":"Yang","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2017.04.010_bib66","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pnpbp.2014.02.003","article-title":"Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats","volume":"51","author":"Zhang","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.04.010_bib67","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1126\/science.1100747","article-title":"Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase","volume":"306","author":"Zimmermann","year":"2004","journal-title":"Science"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T07:10:49Z","timestamp":1617606649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081730151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":67,"alternative-id":["S002839081730151X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.04.010","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}